Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Anat Achiron,Mathilda Mandel,Sapir Dreyer-Alster,Gil Harari,David Magalashvili,Polina Sonis,Mark Dolev,Shay Menascu,Shlomo Flechter,Rina Falb,Michael Gurevich +10 more
Reads0
Chats0
TLDR
The National Multiple Sclerosis Society and other expert organizations recommended that all patients with MS should be vaccinated against COVID-19 as discussed by the authors, however, they did not recommend that all MS patients with mild relapses be vaccinated.Abstract:
Background and Aims:The National Multiple Sclerosis Society and other expert organizations recommended that all patients with multiple sclerosis (MS) should be vaccinated against COVID-19. However,...read more
Citations
More filters
Journal ArticleDOI
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
Sokratis A. Apostolidis,Mihir Kakara,Mark M Painter,Rishi R. Goel,Divij Mathew,Kerry Lenzi,Ayman Rezk,Kristina R. Patterson,Diego A. Espinoza,Jessy C. Kadri,Daniel M. Markowitz,Clyde E. Markowitz,Ina Mexhitaj,Dina A. Jacobs,Allison Babb,Michael R. Betts,Eline T. Luning Prak,Daniela Weiskopf,Alba Grifoni,Kendall A. Lundgreen,Sigrid Gouma,Alessandro Sette,Alessandro Sette,Paul Bates,Scott E. Hensley,Allison R. Greenplate,E. John Wherry,Rui Li,Amit Bar-Or +28 more
TL;DR: In this article, an anti-CD20 monoclonal antibody (aCD20) was used to reduce spike-specific and receptor-binding domain (RBD)-specific antibody and memory B cell responses in most patients.
Journal ArticleDOI
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.
Parakkal Deepak,Wooseob Kim,Michael A. Paley,Monica Yang,Alexander Carvidi,Emanuel G Demissie,Alia A El-Qunni,Alem Haile,Katherine Huang,Baylee Kinnett,Mariel J. Liebeskind,Zhuoming Liu,Lily E McMorrow,Diana Paez,Niti Pawar,Dana C. Perantie,Rebecca E Schriefer,Shannon E Sides,Mahima Thapa,Maté Gergely,Suha Abushamma,Sewuese E. Akuse,Michael K. Klebert,Lynne M. Mitchell,Darren Nix,Jonathan Graf,Kimberly E. Taylor,Salim Chahin,Matthew A. Ciorba,Patricia P. Katz,Mehrdad Matloubian,Jane A. O’Halloran,Rachel M. Presti,Gregory F. Wu,Sean P. J. Whelan,William Buchser,Lianne S. Gensler,Mary C. Nakamura,Ali H. Ellebedy,Alfred H.J. Kim +39 more
TL;DR: In this paper, the immunogenicity of mRNA-based SARS-CoV-2 vaccines in patients with chronic inflammatory disease (CID) was evaluated in an observational cohort study.
Journal ArticleDOI
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
TL;DR: In this article , the efficacy of covid-19 vaccines was compared between immunocompromised and non-immunocompensated patients. But, the results showed that a third dose of a covid19 mRNA vaccine was associated with seroconversion among vaccine nonresponders with solid cancers, haematological cancers, and immune mediated inflammatory disorders, although response was variable in transplant recipients.
Journal ArticleDOI
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Maria Pia Sormani,Matilde Inglese,Irene Schiavetti,Luca Carmisciano,Alice Laroni,Caterina Lapucci,Giorgio Da Rin,Carlo Serrati,Ilaria Gandoglia,Tiziana Tassinari,Germana Perego,Giampaolo Brichetto,Paola Gazzola,Antonio Mannironi,Maria Laura Stromillo,Cinzia Cordioli,Doriana Landi,Marinella Clerico,Elisabetta Signoriello,Jessica Frau,Maria Teresa Ferrò,Alessia Di Sapio,Livia Pasquali,Monica Ulivelli,Fabiana Marinelli,Graziella Callari,Rosa Iodice,Giuseppe Liberatore,Francesca Caleri,Anna Maria Repice,Susanna Cordera,Mario Alberto Battaglia,Mario Alberto Battaglia,Marco Salvetti,Diego Franciotta,Antonio Uccelli,Alessandro Maglione,Alessio Signori,Aniello Iovino,Carolina Gabri Nicoletti,Chiara Rosa Mancinelli,Daiana Bezzini,Daniele Carmagnini,Davide Brogi,Eduardo Nobile Orazio,Eleonora Cocco,Enri Nako,Ester Assandri,Federica Baldi,Filippo Ansaldi,Francesca Bovis,Gabriele Siciliano,Gaia Cola,Giacomo Lus,Giancarlo Icardi,gianmarco bellucci,Girolama Alessandra Marfia,Giulia Vazzoler,Giuseppe Trivelli,Ilaria Maietta,Laura Sticchi,Lorena Lorefice,Lucia Ruggiero,Marcello Manzino,Margherita Monti Bragadin,Maria Chiara Buscarinu,Maria Gagliardi,Maria Teresa Rilla,Marta Ponzano,Marzia Fronza,Massimo Del Sette,Matteo Scialabba,Michele Bedognetti,Nicola De Rossi,Nicola De Stefano,Rachele Bigi,Raffaele Dubbioso,Roberta Reniè,Sabrina Fabbri,Sarah Rasia,Simona Rolla,Stefan Platzgummer,Valentina Carlini +82 more
TL;DR: In this article, a prospective multicenter cohort study was designed to evaluate the effect of the vaccine on SARS-CoV-2 antibody response in patients with Multiple Sclerosis (pwMS).
Journal ArticleDOI
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
Yolanda Braun-Moscovici,Marielle Kaplan,Maya Braun,Doron Markovits,Samy Giryes,K. Toledano,Y. Tavor,Katya Dolnikov,Alexandra Balbir-Gurman +8 more
TL;DR: In this paper, the authors evaluated the humoral response after two doses of mRNA vaccine against SARS-CoV-2, in patients with inflammatory rheumatic diseases treated with immunomodulating drugs and the impact on IRD activity.
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.
Ugur Sahin,Alexander Muik,Evelyna Derhovanessian,Isabel Vogler,Lena M. Kranz,Mathias Vormehr,Alina Baum,Kristen E. Pascal,Jasmin Quandt,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Carsten Boesler,Corinna Rosenbaum,Marie Cristine Kühnle,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Katalin Karikó,Tania Palanche,Boris Fischer,Armin Schultz,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Kena A. Swanson,Jakob Loschko,Ingrid L. Scully,Mark Cutler,Warren Kalina,Christos A. Kyratsous,David A. Cooper,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +41 more
TL;DR: The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
Journal ArticleDOI
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Gustavo Luna,Peter Alping,Joachim Burman,Katharina Fink,Anna Fogdell-Hahn,Martin Gunnarsson,Jan Hillert,Annette Langer-Gould,Jan Lycke,Petra Nilsson,Jonatan Salzer,Anders Svenningsson,Magnus Vrethem,Tomas Olsson,Fredrik Piehl,Fredrik Piehl,Thomas Frisell +16 more
TL;DR: Patients with MS are at a generally increased risk of infections, and this differs by treatment; among newer treatments, off-label use of rituximab was associated with the highest rate of serious infections.
Journal ArticleDOI
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study
Amit Bar-Or,Jonathan Calkwood,Cathy Chognot,Joanna Evershed,Edward Fox,Ann Herman,Marianna Manfrini,John McNamara,Derrick S. Robertson,Daniela Stokmaier,Jeanette K. Wendt,Kevin L. Winthrop,Anthony Traboulsee +12 more
TL;DR: In this article, the effects of Ocrelizumab (OCR)-treatment on immune responses in patients with relapsing multiple sclerosis (RS) were evaluated in the VELOCE study.
Journal ArticleDOI
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
Anat Achiron,Mark Dolev,Shay Menascu,Daniela Noa Zohar,Sapir Dreyer-Alster,Shmuel Miron,Emanuel Shirbint,David Magalashvili,Shlomo Flechter,Uri Givon,Diana Guber,Yael Stern,Michael Polliack,Rina Falb,Michael Gurevich +14 more
TL;DR: In this article, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed, since vaccination against coronavirus disease 2019 (COVID-19) became available.
Related Papers (5)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.
Céline Louapre,Nicolas Collongues,B. Stankoff,C. Giannesini,Caroline Papeix,C. Bensa,Romain Deschamps,Alain Créange,Abir Wahab,Jean Pelletier,Olivier Heinzlef,Pierre Labauge,Laurent Guilloton,Guido Ahle,Mathilde Goudot,Kévin Bigaut,David Laplaud,Sandra Vukusic,Catherine Lubetzki,Jérôme De Seze +19 more
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
Sokratis A. Apostolidis,Mihir Kakara,Mark M Painter,Rishi R. Goel,Divij Mathew,Kerry Lenzi,Ayman Rezk,Kristina R. Patterson,Diego A. Espinoza,Jessy C. Kadri,Daniel M. Markowitz,Clyde E. Markowitz,Ina Mexhitaj,Dina A. Jacobs,Allison Babb,Michael R. Betts,Eline T. Luning Prak,Daniela Weiskopf,Alba Grifoni,Kendall A. Lundgreen,Sigrid Gouma,Alessandro Sette,Alessandro Sette,Paul Bates,Scott E. Hensley,Allison R. Greenplate,E. John Wherry,Rui Li,Amit Bar-Or +28 more